MedTrace Logo

A Phase II Study of Anecortave Acetate for the Treatment of Exudative Age-Related Macular Degeneration

NCT00346957 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 128

Last updated 2012-03-06

No results posted yet for this study

Summary

The purpose of the study is to determine the concentration of anecortave acetate (15 or 30 mg versus placebo) that is safe and effective for the inhibition of the growth of blood vessels in the retina in patients with wet AMD.

Conditions

Interventions

DRUG

Anecortave acetate 30 mg

0.5ml administered onto the sclera once every six months for 24 months

DRUG

Anecortave Acetate 15 mg

0.5ml administered onto the sclera once every six months for 24 months

DRUG

Anecortave Acetate 3 mg

0.5ml administered onto the sclera once every six months for 24 months

OTHER

Anecortave Acetate Vehicle

0.5ml administered onto the sclera once every six months for 24 months

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-04-30
Primary Completion
2003-04-30
Completion
2003-04-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00346957 on ClinicalTrials.gov